Modelling the opportunity for cost-savings or patient access with biosimilar adalimumab and tocilizumab: a European perspective.
J Med Econ
; 27(1): 952-962, 2024.
Article
en En
| MEDLINE
| ID: mdl-39015093
ABSTRACT
OBJECTIVES:
Biosimilars improve patient access by providing cost-effective treatment options. This study assessed the potential for savings and expanded patient access with increased use of two biosimilar disease modifying anti-rheumatic drugs (DMARDs) (a) approved adalimumab biosimilars and (b) the first tocilizumab biosimilar, representing an established biosimilar field and a recent biosimilar entrant in France, Germany, Italy, Spain, and the United Kingdom (UK).METHODS:
Separate ex-ante analyses were conducted for each country, parameterized using country-specific list prices, unit volumes annually, and market shares for each therapy. Discounting scenarios of 10%, 20%, and 30% were tested for tocilizumab. Outputs included direct cost-savings associated with drug acquisition or the incremental number of patients that could be treated if savings were redirected. Two biosimilar conversion scenarios were tested.RESULTS:
Savings associated with a 100% conversion to adalimumab biosimilar ranged from 10.5 to 187 million (UK and Germany, respectively), or an additional 1,096 to 19,454 patients that could be treated using the cost-savings. Introduction of a tocilizumab biosimilar provided savings up to 29.3 million in the most conservative scenario. Exclusive use of tocilizumab biosimilars (at a 30% discount) could increase savings to 28.8 to 113 million or expand access to an additional 43% of existing tocilizumab users across countries.CONCLUSION:
This study demonstrates the benefits that can be realized through increased biosimilar adoption, not only in an untapped tocilizumab market, but also through incremental increases in well-established markets such as adalimumab. As healthcare budgets continue to face downwards pressure globally, strategies to increase biosimilar market share could prove useful to help manage financial constraints.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Ahorro de Costo
/
Antirreumáticos
/
Anticuerpos Monoclonales Humanizados
/
Biosimilares Farmacéuticos
/
Adalimumab
Límite:
Humans
País/Región como asunto:
Europa
Idioma:
En
Revista:
J Med Econ
Asunto de la revista:
SERVICOS DE SAUDE
Año:
2024
Tipo del documento:
Article
País de afiliación:
Canadá